2025-26 Financial statements

Cystic Fibrosis Canada is fully committed to transparency and accountability of financial information. We remain in a favourable financial position as we continue to strategically invest generous donor dollars into vital cystic fibrosis research and care, to ensure donations achieve the greatest impact.

Statement of Operations

(in thousands of dollars)
Year Ended January 31, 2026, with comparative information for 2025

Revenue	2026	2025
Community events	$ 6,405	$ 6,209
Annual giving	1,863	1,826
Leadership giving	1,373	1,267
Kin Canada	352	548
Corporate giving	710	929
Other	1,176	1,358
Bequests	3,363	2,347
Total	**$ 15,242**	**$ 14,484**
Less direct fundraising costs	3,185	3,223
Net fundraising revenue	12,057	11,261

Expenses	2026	2025
Program		
Research	$ 4,157	$ 4,069
Healthcare	1,331	1,312
Community engagement	1,322	1,747
Advocacy	511	534
Total	**$ 7,321**	**$ 7,662**
Other		
Administration	1,960	1,956
Fundraising	1,944	1,560
Total	**$ 3,904**	**$ 3,516**
Excess of revenue over expenses before the undernoted	**832**	**83**

Investment Income	2026	2025
Realized gains on investments	$ 237	$ 361
Change in unrealized gain (loss) on investments	(60)	126
Total	**$ 177**	**$ 487**
Excess of revenue over expenses	**1,009**	**570**

Statement of Financial Position

(in thousands of dollars)
Year Ended January 31, 2026, with comparative information for 2025

Assets	2026	2025
Current Assets		
Cash and equivalents	$ 10,460	$ 8,433
Short-term investments	1,263	1,337
Receivables and other assets	618	955
Total	**$ 12,341**	**$ 10,725**
Contributions receivable	185	182
Long-term investments	4,801	4,694
Capital assets	596	612
Total	**$ 17,923**	**$ 16,213**

Liabilities and Net Assets	2026	2025
Current Liabilities		
Accounts payable and accrued liabilities	$ 892	$ 511
Deferred revenue	1,097	712
Total	**$ 1,989**	**$ 1,223**
Long-term liabilities	733	798
Net Assets		
Endowment	$ 94	$ 94
Internally restricted for research and healthcare	2,453	2,704
Invested in capital assets	256	230
Internally reserved for strategic impact fund	2,509	1,500
Unrestricted	9,889	9,664
Total	**$ 17,923**	**$ 16,213**

Cystic Fibrosis Fibrose kystique Canada | w/o limits

Statement of Changes in Net Assets

(in thousands of dollars)

Year ended January 31, 2026, with comparative information for 2025

	Endow-ment	Internally restricted for research and clinics	Invest in capital assets	Internally reserved for strategic impact fund	Unrestricted	**2026 Total**	**2025 Total**
Net assets, beginning of year	$ 94	$ 2,704	$ 230	$ 1,500	$ 9,664	**$ 14,192**	**$ 13,622**
Excess (deficiency) of revenue over expenses			(52)		$ 1,061	**$ 1,009**	**$ 570**
Investment in capital assets			$ 78		(78)	**-**	**-**
Transfer between funds		(251)		$ 1,009	(758)	**-**	**-**
Net assets, end of year	$ 94	$ 2,453	$ 256	$ 2,509	$ 9,889	**$ 15,201**	**$ 14,192**

Statement of Fundraising Revenue

(Net of direct fundraising costs)



- Community events 35%
- Bequests 28%
- Leadership Giving 11%
- Other 10%
- Annual Giving 7%
- Corporate Giving 6%
- Kin Canada 3%

Note: Fundraising revenue excludes realized and unrealized gains/losses on investments.

Expenses



- Cost of programs 48%
- Cost of fundraising 34%
- Cost of administration 13%

Complete audited financial statements are available on our website at cysticfibrosis.ca.

Accredited
IMAGINE CANADA

We are proud to be accredited by Imagine Canada's Standards Program, recognizing our commitment to transparency, accountability, and strong governance.